Heartland Veterinary Suppply & Pharmacy
Contact Us

SucroMate Equine


SucroMate Equine


SucroMate Equine

  • Veterinarian Prescription (Rx) Required
  • Next-Day Delivery
  • Deslorelin Acetate
  • For use in horses
SKU: 354010-RX
Price: $336.00

Quantity:
RX required for this item.
Click here for our full Prescription Policy and Form


Why SUCROMATE™ EQUINE?

Features of SucroMate          

  • Contains 1.8 mg/mL deslorelin acetate in a long-acting base    
  • Dose determination, field-based efficacy and safety and target animal safety studies involving hundreds of mares in three countries
  • Manufactured according to Current Good Manufacturing Principles    
  • Raw materials conform to USP standards    


Benefits of SucroMate

  • Reliably advances ovulation to within 48hrs, in 80% of mares treated -- Increases the efficiency of the breeding operation
  • FDA approved -- Veterinarians and owners/managers can have confidence in the reliability and consistent quality of the product
  • Batch to batch consistency and quality -- Veterinarians and owners/managers can have confidence in the product
  • Clinics can easily purchase and keep supplies on hand  -- Veterinarians will not lose time requesting compounded supplies
Thorn BioScience


Because this is a cooler item, it must Ship OVERNIGHT Delivery to insure the integrity of the product. This items ships in a styrofoam cooler with ice packs on Monday-Thursdays (on orders placed before 2:00p.m.) 

Click here for our Vaccine Shipping Schedule.
Product Rating: (0.00)   # of Ratings: 0   (Only registered customers can rate)

There are no comments for this product.

SUCROMATE™ EQUINE

Thorn BioScience

Sterile Suspension

(DESLORELIN ACETATE)

INJECTABLE SUSTAINED RELEASE GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG

FOR USE IN HORSES ONLY

REFRIGERATE AFTER EACH USE

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

SucroMate™ Equine is a sterile, synthetic gonadotropin-releasing hormone (GnRH) analog (deslorelin acetate) suspension. SucroMate™ Equine is a sustained release formulation that forms an in situ gel upon intramuscular injection. Deslorelin acetate is [(6-D-tryptophan-9-(N-ethyl-L-prolinamide)-10-deglycinamide)] GnRH. The molecular weight is 1282.6.

SUCROMATE™ EQUINE

The deslorelin acetate structural formula is:

[(6-D-tryptophan-9-(N-ethyl-L-prolinamide)-10-deglycinamide)] GnRH

Each mL contains 1.8 mg/mL deslorelin acetate (1.7 mg/mL deslorelin) for injection as a sterile suspension in sucrose acetate isobutyrate/propylene carbonate (70:30 wt:wt). Ten doses per vial.

INDICATION:

SucroMate™ Equine is indicated for inducing ovulation within 48 hours of treatment in cyclic estrous mares with an ovarian follicle between 30 and 40 mm in diameter.

DOSAGE and ADMINISTRATION:

Shake well before use. Administer 1 mL (one dose) per estrus cycle, 48 hours prior to desired ovulation. Verify that the mare is in estrus and has at least one ovarian follicle between 30 and 40 mm in diameter.

SucroMate™ Equine is a suspension of deslorelin and settling will occur over time. Warm the product for 2 minutes by rolling the vial between the palms (to reach room temperature), or allow the vial to sit for 30 minutes at room temperature prior to administration. Shake the vial vigorously for 1 minute before use. Administer a 1 mL intramuscular injection into the thick musculature of the neck.

Prior to administration, it should be determined by rectal palpation and/or ultrasonography that the cyclic estrous mare has an ovarian follicle greater than 30 mm in diameter. Effectiveness is contingent upon accurate diagnosis of estrus and detection of a developing follicle between 30 and 40 mm in diameter. Only 1 mL should be administered per mare during a given estrus.

CONTRAINDICATIONS: SucroMate™ Equine is contraindicated in horses known to be hypersensitive to deslorelin acetate.

WARNING:

For use in horses (estrous mares) only. Do not use in horses intended for human consumption. For intramuscular (IM) use only. Do not administer intravascularly. Not for use in humans. Keep this and all drugs out of reach of children.

HUMAN WARNING - NOT FOR HUMAN USE:

Pregnant women and women of childbearing age should exercise caution when handling this product. Accidental administration may lead to a disruption of the menstrual cycle. Direct contact with the skin should be avoided. If exposure occurs, contact areas should be washed immediately with alcohol followed by soap and water, as this product is insoluble in water. In case of accidental human injection, consult a physician immediately.

PRECAUTIONS: The use of GnRH analogs in cycling mares has been associated with prolonged interovulatory intervals. SucroMate™ Equine has not been evaluated in mares less than 3 years of age.

ADVERSE REACTIONS:

Injection site swelling was observed following the administration of SucroMate™ Equine (deslorelin acetate) during the effectiveness and safety studies; all injection site swellings resolved within 5 days, and 7 - 14 days, respectively.

For technical assistance or to report a suspected adverse reaction call 1-800-456-1403.

CLINICAL PHARMACOLOGY:

Deslorelin induces ovulation by increasing the levels of endogenous luteinizing hormone. SucroMate™ Equine (deslorelin acetate) has been shown to induce ovulation within 48 hours of treatment in 78% of mares with a developing follicle greater than 30 mm in diameter. This product is intended to optimize breeding management through induction of ovulation within 48 hours.

EFFECTIVENESS:

Two hundred eighty three (283) mares, ranging in age from 2 to 20 years (mean 10.6 years) of age randomly received either SucroMate™ Equine or placebo and were evaluated for field safety under actual conditions of use. A total of 191 mares (97 placebo and 94 mares in the SucroMate™ Equine group) were evaluated for effectiveness. Breeds included Standardbreds, Thoroughbreds, Quarter Horses and Paints. Mares were evaluated for up to 3 cycles to determine if SucroMate™ Equine induced ovulation in cyclic mares, and to determine the effects on the interovulatory interval, pregnancy rate and general health characteristics of the resultant foals.

The proportion of mares ovulating within 48 hours of treatment was significantly higher in the SucroMate™ Equine group as compared to the placebo group (see Table 1).

Table 1. Percentage of Mares Ovulating Within 48 Hours of Treatment

(Yes = ovulated / No = did not ovulate)

 

Placebo (1.0 mL)

SucroMate™ Equine (1.0 mL)

P value

1st Cycle

 

 

 

Number of mares treated

97

94

 

Yes

23 (24%)

68 (72%)

p = 0.000*

No

73 (75%)

25 (27%)

 

Not determined

1 (1%)

1 (1%)

 

2nd Cycle

 

 

 

Number of mares treated

25

35

 

Yes

9 (36%)

29 (83%)

p = 0.000*

No

16 (64%)

6 (17%)

 

3rd Cycle

 

 

 

Number of mares treated

9

13

 

Yes

3 (33%)

12 (92%)

p = 0.006*

No

6 (67%)

0 (0%)

 

Not determined

0 (0%)

1 (8%)

 

Average % ovulating within 48 hours after treatment in any cycle

31%

82%

 

*statistically significant

Following treatment in each of three estrus cycles, the mean hours to ovulation was reduced in the SucroMate™ Equine treated group compared to the placebo group (See Table 2).

Table 2. Mean Hours to Ovulation

 

Placebo (1.0 mL)

SucroMate™ Equine (1.0 mL)

P value

1st Cycle

91.8 (n=96)

65.1 (n=90)

p = 0.019*

2nd Cycle

83.0 (n=24)

56.2 (n=35)

p = 0.099

3rd Cycle

85.3 (n=9)

41.0 (n=12)

p = 0.153

*statistically significant

The interovulatory interval was calculated between cycles for all mares that did not become pregnant in the previous cycle. There was no significant difference in the length of interovulatory intervals between the SucroMate™ Equine treated group and the placebo-treated mares as represented in Table 3.

Table 3. Mean Interovulatory Interval (days)

 

Placebo (1.0 mL)

SucroMate™ Equine (1.0 mL)

P value

Cycles 1-2

26.1 (n=27)

22.3 (n=32)

p = 0.182

Cycles 2-3

21.3 (n=9)

18.5 (n=11)

p = 0.336

Cycles 3-4

13.0 (n=1)

18.0 (n=1)

 

Twins were detected in 8 placebo mares and 2 SucroMate™ Equine mares. The nursing behavior, mobility and general health of the live foals were similar for foals from mares in the SucroMate™ Equine and placebo groups. See Table 4 for a summary of the foaling and foal assessment data.

Table 4. Foaling and Foal Assessment Data*

 

Treatment Group

Assessment

Placebo

SucroMate™ Equine

Mares confirmed pregnant in 1999 breeding season out of total # of mares per group % (n/N)

83% (118/143)

81% (114/140)

Mares confirmed to have a live foal out of # of pregnant mares % (n/N)

94% (111/118)

84% (96/114)

Mares confirmed to have a stillbirth out of # of pregnant mares % (n/N)

0% (0/118)

3.0% (3/114)

72 Hour-General Health Foal Assessment % (n/N)

Good

80% (89/111)

79% (76/96)

Satisfactory

16% (18/111)

20% (19/96)

Not Satisfactory

2% (2/111)

2% (2/96)

4 Week-General Health Foal Assessment % (n/N)

Good

34% (38/111)

36% (35/96)

Not Assessed

66% (73/111)

67% (64/96)

*data could not be obtained on all mares

When administered to cyclic, estrous mares with a pre-ovulatory follicle between 30 mm and 40 mm in diameter, a single, 1 mL injection of SucroMate™ Equine (1.8 mg of deslorelin acetate/mL) resulted in ovulation within 48 hours of treatment in 78% of treated mares. The length of the inter-ovulatory interval between cycles was not altered. The pregnancy rate of the treated mares was similar to the placebo mares.

Animal Safety: In the target animal safety study, 32 reproductively sound, mixed breed mares, ranging in age from 3-15 years were administered 1X (1 mL), 3X (3 mL) and 5X (5 mL) the recommended 1.8 mg dose of SucroMate™ Equine for three consecutive cycles. Treatment with SucroMate™ Equine at all doses reduced the mean hours to ovulation during all three treatment cycles compared to the placebo group. Of the sixty-five treatment experiences for the SucroMate™ Equine treated mares across the three cycles 55 (84.6%) were followed by ovulation within 48 hours compared to five of twenty-three (21.7%) for placebo mares. There was no statistically significant effect on the length of estrus at any dose level.

Some mares in all SucroMate™ Equine treatment groups exhibited mild to moderate swelling at the injection site six hours post-injection during all three treatment cycles. Sensitivity to touch was more frequent in the 5X dose group at Day 1 post-treatment in Cycle 1, and at Days 2 and 4 post-treatment in Cycle 2, and in the 3X group at Day 1 post-treatment in Cycle 1. All injection site reactions in the 1X treated mares resolved by Day 3 post-treatment. Two mares, one 3X mare and one 5X mare, had swelling and hardness noted at injection sites at Day 7 post-treatment. The incidence of injection site reactions for the placebo, 1X, 3X and 5X groups was 37%, 75%, 50%, and 87%, respectively.

The LH concentrations in the SucroMate™ Equine treated groups in all three cycles exhibited an expected surge following treatment and prior to ovulation, followed by lower concentrations during the midluteal phase, with a gradual return to pretreatment levels.

The mean inter-ovulatory interval in the SucroMate™ Equine groups ranged from 17.8 - 23 days compared to 21 - 23.5 days in the placebo group.

All mares that ovulated after the 3rd treatment with SucroMate™ Equine or placebo were bred. These mares were bred until they became pregnant (not to exceed three cycles). In the placebo group, seven mares ovulated after the 3rd treatment and were bred. Six of the seven mares became pregnant (85.7%). In the 1X group, six mares ovulated after the 3rd treatment and were bred. All six became pregnant (100%). In the 3X group, eight mares ovulated after the 3rd treatment and were bred. Six of the eight mares became pregnant (75%). In the 5X group, five mares ovulated after the 3rd treatment and all became pregnant (100%).

There were no significant differences across the treatment groups in terms of time to pregnancy or the number and proportion of mares that became pregnant after three consecutive SucroMate™ Equine injections.

In a separate dose tolerance study mares received a single IM injection of placebo (8 mares) or SucroMate™ Equine at 10X the recommended of 1.8 mg dose (8 mares). One SucroMate™ Equine10X mare exhibited moderate tremors and hives at 6 hours post-treatment.

STORAGE:

Store refrigerated at 2-8°C.

HOW SUPPLIED:

One (1) 10 mL vial (10 doses) per vial

NADA 141-319, Approved by FDA.

NDC NUMBER: 51330-167-10

Developed and Manufactured by: Thorn BioScience LLC, Louisville, KY 40204 USA

www.thornbioscience.com

To report suspected adverse reactions or to obtain a copy of the Material Data Safety Sheet (MSDS), or for technical assistance call 1-800-456-1403 or www.thornbioscience.com

SP-1000108-00

NAC No.: 1545000.0

IMPORTANT VETERINARIAN INFORMATION
We are unable to ship prescriptions into Arkansas, Louisiana, Mississippi, and North Carolina
*Required Information. Please complete form for each pet:













*Would you like us to contact your veterinarian for this prescription?








Low Price Guarantee

Low Price Guarantee

If the item has this emblem, we will gladly match any competitors’ current advertised price.

Competitor must be based in the United States, sorry we cannot honor foreign country prices.

Free Shipping

Fast & Free Shipping

Orders received before 1:00pm M-F (CST) will be processed that same business day.

Free shipping on non-vaccine orders of $75 or more (before tax).

Satisfaction Guarantee

Satisfaction Guarantee

Every purchase you make at HeartlandVetSupply.com is covered by our satisfaction guarantee.

If you are not completely satisfied, please contact us within 30 days.

Heartland Veterinary Supply & Pharmacy is a Vet-VIPPS Accredited Pharmacy Veterinary-Verified Internet Practice Site

Because buying prescription drugs from the Internet is easy, finding a safe source for those medicines is not.

Vet VIPPS Accredited

Located in Hastings, Nebraska, Heartland Veterinary Supply & Pharmacy started as a Veterinary Clinic in 1981, specializing in the health and wellness of the equine, canine and feline species. We have a licensed Veterinarian and Pharmacist on site, as well as a helpful team with the knowledge and products you need to keep your horse, dog or cat healthy and happy. The Heartland Staff is dedicated to fast, courteous service. See what our customers are saying.

Compendium of Veterinary Products

Use the online Compendium of Veterinary Products to view prescription products Indications, Dosage, Precautions, Ingredients, and Side Effects

Shipping Policy
Return Policy
Request Catalog
Follow Us on Pinterest
Instagram
Newsletter

Arkansas

Louisiana

Mississippi

North Carolina

West Virginia

Connecticut

Delaware

New Hampshire

New Jersey

New York

Illinois


employees
office

Please Note: Images displayed for products may not be identical to the product that you receive, or reflect actual size or dosage.

PHONE: 800-934-9398 | FAX: 888-424-0484

EMAIL us at: info@heartlandvetsupply.com | 401 W. 33rd Street, Hastings, NE 68901

© HeartlandVetSupply.com 2014. All Rights Reserved

Powered by AspDotNetStorefront